AVXL has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AVXL has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Anavex Life Sciences has the Financial Strength Rank of 8. It shows strong financial strength and is unlikely to fall into distressed situations.
Good Sign:
Anavex Life Sciences Corp shows strong financial strength.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.Anavex Life Sciences has no long-term debt (1). As of today, Anavex Life Sciences's Altman Z-Score is 0.00.
(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, Anavex Life Sciences's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Anavex Life Sciences's Financial Strength distribution charts can be found below:
* The bar in red indicates where Anavex Life Sciences's Financial Strength falls into.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Anavex Life Sciences's Interest Expense for the months ended in Dec. 2023 was $0.00 Mil. Its Operating Income for the months ended in Dec. 2023 was $-11.29 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil.
Anavex Life Sciences's Interest Coverage for the quarter that ended in Dec. 2023 is
Anavex Life Sciences had no long-term debt (1). |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
Anavex Life Sciences's Debt to Revenue Ratio for the quarter that ended in Dec. 2023 is
Debt to Revenue Ratio | = | Total Debt (Q: Dec. 2023 ) | / | Revenue | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Revenue | |
= | (0 | + | 0) | / | 0 | |
= | N/A |
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Anavex Life Sciences has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anavex Life Sciences (NAS:AVXL) Financial Strength Explanation
The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.
Anavex Life Sciences has the Financial Strength Rank of 8. It shows strong financial strength and is unlikely to fall into distressed situations.
Thank you for viewing the detailed overview of Anavex Life Sciences's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.
Christopher U Missling | director, officer: President, CEO, CFO, Treasurer, other: Secretary | 61 MOULTON ST, CAMBRIDGE MA 02138 |
Athanasios Skarpelos | 10 percent owner | 14,RUE KLEBERG, GENEVA V8 CH-1201 |
Jiong Ma | director | 445 PARK AVENUE, 9TH FLOOR, NEW YORK NY 10022 |
Elliot Favus | director | 51 W 52ND STREET, 7TH FLOOR, NEW YORK NY 10091 |
Donhauser Peter D.o. | director | REGINA-KIRCHMAIER STRASSE 4, KAUFBEUREN 2M 87600 |
Sandra Boenisch | officer: PFO & Treasurer | 51 WEST 52ND STREET, 7TH FLOOR, NEW YORK NY 10019 |
Claus Vander Velden | director | PO BOX MUENSTEREIFELER ST., COLOGNE 2M 50937 |
Steffen Thomas | director | FALLMERAYER STR. 19, MUNICH 2M 80796 |
Bernd Metzner | director | 51 W 52ND STREET, 7TH FLOOR, NEW YORK NY 10019 |
George F Tidmarsh | director, officer: Executive Director | |
John Robert Chisholm | director | 16308 36A AVENUE, SURREY A1 V3S 0X5 |
William Sean Lowry | director | 1172 BAY STREET, SUITE 300, ONTARIO Z4 M5S1L9 |
David L. Tousley | director | 14610 PAWNEE LANE, LEAWOOD KS 66224 |
Harvey Lalach | director, officer: President CEO CFO | 4837 CANYON RIDGE CRESENT, KELOWNA A1 V1W 4A1 |
Alison E. Ayers | director | 27 O'CONNOR CIRCLE, WEST ORANGE NJ 07052 |
From GuruFocus
By Stock market mentor Stock market mentor • 01-31-2023
By Marketwired • 06-28-2023
By GlobeNewswire GlobeNewswire • 12-02-2022
By Value_Insider Value_Insider • 12-12-2022
By Stock market mentor Stock market mentor • 02-07-2023
By Value_Insider Value_Insider • 12-02-2022
By Marketwired • 11-06-2023
By sperokesalga sperokesalga • 06-01-2023
By Marketwired • 08-01-2023
By Value_Insider Value_Insider • 11-08-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.